SAMSUNG PHARMACEUTICAL.CO.,Ltd. Q3 revenue KRW 10.2 billion, loss of KRW 2.8 billion from the main business
AI summary · Not investment advice
Samsung Pharm sold KRW 10.2 billion in Q3 and lost KRW 2.8 billion from its main business; sales fell 14.9% from a year earlier and rose 3.1% from the prior quarter.
Operating profit · 3 months
KRW -2.8 billion
Key facts
- Revenue (3 months)
- KRW 10.2 billion
- Net income (3 months)
- KRW -7.8 billion
- Period
- Q3 (cumulative 2026.01.01 ~ 2026.09.30)
- Revenue (prior-year 3 months)
- KRW 12.0 billion
- Revenue (year to date)
- KRW 29.1 billion
- Operating profit (prior-year 3 months)
- KRW -3.9 billion
- Operating profit (year to date)
- KRW -9.8 billion
- Net income (prior-year 3 months)
- KRW -30.2 billion
- Net income (year to date)
- KRW -55.6 billion
Commentary
AI commentary · Not investment advice
What happened
Samsung Pharm reported its separate-basis results for the third quarter of 2026. Sales for the latest 3 months were KRW 10.21 billion. That is down 14.9% from the same 3 months a year earlier, which had KRW 12.00 billion. Sales rose 3.1% from the previous quarter. Cumulative sales this year are KRW 29.13 billion.
In the company's terms
The company made an operating loss (loss from its main business) of KRW 2.80 billion in the latest 3 months. A year earlier, the operating loss for the same period was KRW 3.85 billion. The cumulative operating loss this year is KRW 9.83 billion.
What changes for shareholders
The final result after all costs, taxes and other items was a net loss of KRW 7.75 billion in the latest 3 months. A year earlier, the net loss for the same period was KRW 30.17 billion. The cumulative net loss this year is KRW 55.65 billion.
Comments
No comments yet
Comments from shareholders will appear here.
Ad
Verify your holdings and catch the next disclosure
Verify the stocks you hold and get new disclosures as app alerts.

App design sample
Get the next disclosure as an app alert
Get app alerts for new disclosures and stake changes on your watchlist
S